Loading
A phase 1/2 trial of Pemetrexed, Carboplatin, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) is a phase 1/2 interventional study registered as NCT07070440 by Dizal Pharmaceuticals, with 180 participants planned, started 2025-07-16 and due to reach its primary completion in 2027-06. Interventions recorded: DZD6008, Pemetrexed, Carboplatin, Docetaxel. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/